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INTRODUCTION
Low Dose Aspirin: An Eective Chemoprophylaxis for Preventing 
Venous Thromboembolic Events
Javad Parvizi MD, FRCS, Antonia F. Chen MD, MBA, Camilo Restrepo MD, Ronald Huang MD, Jenny Cai BS, William J. Hozack MD, Jess H. Lonner MD.
Investigation performed at the Rothman Institute at Thomas Jeerson University, Philadelphia, PA.
MATERIALS AND METHODS
DISCUSSION
REFERENCES
Table 2: Complication rates in patients receiving ASA 81mg bid vs. 325mg bid.
mg=milligrams; bid=Bis in die (twice a day); DVT=Deep venous thrombosis.
 The available guidelines, endorsed by Surgical Care Improvement Project (SCIP), 
have advocated that aspirin (ASA) is a safe and eective strategy for venous thromboem-
bolic events (VTE) prophylaxis following total joint arthroplasty (TJA). The optimal dose 
of aspirin for this purpose is not known. The rst guidelines for prevention of VTE that 
were issued by the American Academy of Orthopedic Surgeons recommended 325 mg 
Bis in die (twice a day) (bid) for this purpose with the recommendation having a 1C grade 
(little evidence to support the recommendation). It is known that platelet aggregation 
inhibition occurs at lower doses. Traditionally, ASA 81mg has been used as a cardio-
protective medication. Additionally, all available randomized studies, including the sen-
tinel study on Pulmonary Embolism Prevention (PEP) trial1-4 have used lower doses of 
ASA. It was our hypothesis that lower dose aspirin is likely to be as eective as higher 
dose aspirin while reducing the gastrointestinal side eects associated with the higher 
dose aspirin. 
 We analyzed a cohort of 2,880 primary TJA patients. All patients were treated with 
post-operative intermittent pneumatic compression while hospitalized. Of these, 2,138 
patients with an average age of 64.6 years [Standard desviation (SD) ±10.4] received en-
teric coated ASA 325mg by mouth, bid for 4 weeks. In the other group, 742 patients with 
an average age of 64.1 years (SD±12.0) received plain ASA 81mg by mouth bid for 4 
weeks. Gender, body mass index (BMI), and comorbidities assessed by the Charlson co-
morbidity index (CCI) were recorded (Table 1). There was no dierence in age, gender, 
CCI, or BMI between the patient populations.  Patients were evaluated for the develop-
ment of symptomatic VTE in the post-operative period using International Classication 
of Diseases version 9 (ICD-9) codes, specically deep vein thrombosis (DVT) and pulmo-
nary embolism (PE). Statistical analysis was performed using Wilcoxon and Fisher’s tests.
 Our ongoing study demonstrates that low dose ASA (81mg bid for four weeks) is as 
eective of a prophylaxis agent as high dose ASA (325mg) following TJA. This is not sur-
prising as all available literature, including many publications related to VTE prophylaxis 
following TJA, demonstrate that low dose aspirin has better antiplatelet aggression 
properties. Continued evaluation of the safety and ecacy of ASA as a prophylactic 
agent and the comparison of the doses continues at our in our prospective study.
 Acute infection rate was also higher in the 325mg ASA group at 5 cases (0.2%) com-
pared to none in the 81mg ASA group.  Finally, there were two mortalities in the 325mg 
ASA group (one in-hospital, one post-discharge) compared to one mortality in the 81mg 
ASA group (post-discharge).  
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 There was no signicant dierence in the incidence of VTE between the two 
groups; 0.1% in the 81mg ASA group (one DVT), compared to 0.2% in the 325mg ASA 
group (2 DVT and 2 PE). Two episodes of gastrointestinal (GI) bleeding occurred in 
the 325mg ASA group, compared to none in the 81mg ASA group.
Table 1: Demographics and procedures in patients receiving ASA 81mg bid vs. 325mg bid.
mg=milligrams; bid=Bis in die (twice a day); SD=Standard deviation; CCI=Charlson comorbidity index; Kg=Kilograms; m2=Square meter;  
THA=Total hip arthroplasty; TKA=Total knee arthroplasty.
Figure 1: Forest plot from the Antitrombotic Trialists’ Combination study4 depicting the protective eect againts 
vascular events among dierent aspirin dosages. Studies using between 75 and 150 mg of aspirin exhibit a greater 
antiplatelet eect than studies with aspirin regimens in between 160 and 325 mg.
No.=Number; mg=milligrams.
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RESULTS
FIGURE 1
Aspirin Evidence: Dose and Eﬃcacy
Indirect comparisons of aspirin doses on vascular events in
hight-risk patients
Aspirin Dose No. of Trials (%)
Odds Ratio for
Vascular Events
500 – 1500 mg 34 19
160 – 325 mg 19 26
75 – 150 mg 12 32
< 75 mg 3 13
Any aspirin 65 23
P<0.0001
0 0.5 1.0 1.5 2.0
Antiplatelet Better Antiplatelet Worse
Aspirin 81mg bid Aspirin 325mg bid p-value
Age (years) mean (SD) 64.1 (12.0) 64.6 (10.4) 0.295
CCI mode (SD) 3 (± 2) 3 (± 1) 0.082
BMI (kg/m2) mean (SD) 29.7 (6.2) 29.5 (5.1) 0.738
LOS (days) mean (SD) 1.9 (1.1) 1.9 (2.2) 0.591
Sex Male 46.2% 45.1% 0.654Female 53.8% 54.9%
Primary THA 40.2% 51.6% <0.001Primary TKA 59.8% 48.4%
Complication ASA 81mg bid ASA 325mg bid p-value(n=742) (n=2138)
DVT 1 (0.1%) 2 (0.1%) 0.764
Pulmonary Embolism 0 (0%) 2 (0.1%) 0.405
Gastrointestinal Bleeding 0 (0%) 2 (0.1%) 0.405
Acute Infection 0 (0%) 5 (0.2%) 0.187
90-day Mortality 1 (0.1%) 2 (0.1%) 0.764
